EMT6 - Syngeneic Model

 

Rincon Bio performs EMT6 syngeneic models to test efficacy of immunotherapies.  Please see below for additional information or to request a quote. 

Breast

Organism: Mus musculus, mouse  /  Cell Type: epithelial  /  Tissue: breast  /  Disease: mammary carcinoma

Notes

EMT6 was established from a transplantable murine mammary carcinoma that arose in a BALB/cCRGL mouse after implantation of a hyperplastic mammary alveolar nodule. The resulting tumor line (named KHJJ) was propagated in BALB/cKa mice and adapted to tissue culture after the 25th animal passage, and the cell line was named EMT. EMT6 is a clonal isolate of EMT isolated in 1971 at Stanford University. 

in vivo

Used as a syngeneic model.  Implanted tumor cells create a model in which to test the efficacy of novel immunotherapies 

Forms solid tumors in some sublines of BALB/c mice

Request Quote

Receive a quote within one business day

Rincon Bio Survival Curve

emt6 survival.png

WHY WORK WITH

RINCON BIO?

DOMESTIC QUALITY at COMPETITIVE PRICES

 

When you work with Rincon Bio, rest assured that all cancer efficacy studies will be performed in the USA, at competitive prices

SPEED TO INITIATION
 

Most efficacy studies can be initiated within two business days.

PERSONAL TOUCH

 

We love our clients!  We take a personal interest in our clients and their studies.